Renal Denervation for Hypertension: Current Evidence and Clinical Perspectives

Area of Science:

• Cardiology
• Nephrology
• Vascular Medicine

Background:

• Hypertension remains a primary driver of cardiovascular morbidity and mortality.
• Progress in hypertension control has stagnated, with significant under-treatment impacting high-risk populations, including women and minority groups.
• Existing pharmacologic therapies have limitations, necessitating exploration of alternative treatment strategies.

Purpose of the Study:

• To review current literature on hypertension diagnosis and treatment.
• To highlight existing disparities in hypertension care.
• To critically evaluate recent randomized controlled trials (RCTs) of renal denervation (RDN) and define its role in hypertension management.

Main Methods:

• Comprehensive literature review of hypertension diagnosis and treatment.
• Analysis of recent randomized controlled trials (RCTs) focusing on renal denervation (RDN).
• Evaluation of RDN's efficacy, safety, and applicability across diverse patient demographics.

Main Results:

• Despite advances, hypertension control rates have plateaued, with notable disparities in care.
• Renal denervation (RDN), utilizing radiofrequency and ultrasound, demonstrates efficacy in reducing blood pressure in recent RCTs.
• RDN is increasingly considered for integration into clinical practice guidelines as an adjunctive therapy.

Conclusions:

• Renal denervation (RDN) presents a promising procedural option for managing resistant hypertension.
• Ensuring equitable access and understanding long-term outcomes in underrepresented populations are critical for RDN implementation.
• Further research is essential to confirm the long-term safety, effectiveness, and impact of RDN across diverse patient groups.